Medifast (NYSE:MED) Director Purchases 43,150 Shares of Stock

Key Points

• Director Parsa Kiai purchased 43,150 Medifast shares at an average price of $11.60, investing $500,540 and increasing his direct ownership by 6.98% to 661,306 shares. He also bought 29,337 shares the previous day.
• Medifast shares recently traded at $11.87, with a market capitalization of approximately $132.7 million. The stock remains unprofitable, with a negative P/E ratio of 5.09 and a 52-week range of $9.22 to $14.67.
• The company beat quarterly earnings and revenue expectations, reporting adjusted EPS of negative $0.28 and revenue of $76.38 million, but analysts maintain a consensus “Reduce” rating with a $12.00 target price.

Medifast Inc (NYSE:MED - Get Free Report) Director Parsa Kiai bought 43,150 shares of the firm's stock in a transaction on Thursday, August 20th. The shares were bought at an average cost of $11.60 per share, with a total value of $500,540.00. Following the transaction, the director directly owned 661,306 shares of the company's stock, valued at approximately $7,671,149.60. This trade represents a 6.98% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Wednesday, August 19th, Parsa Kiai purchased 29,337 shares of Medifast stock. The shares were bought at an average price of $11.66 per share, for a total transaction of $342,069.42.

Medifast Stock Performance

Shares of Medifast stock traded up $0.25 on Friday, reaching $11.87. The stock had a trading volume of 54,923 shares, compared to its average volume of 231,125. The business's 50-day moving average price is $10.92 and its two-hundred day moving average price is $11.06. Medifast Inc has a fifty-two week low of $9.22 and a fifty-two week high of $14.67. The stock has a market cap of $132.71 million, a P/E ratio of -5.09 and a beta of 0.65.

Medifast (NYSE:MED - Get Free Report) last posted its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. As a group, equities analysts forecast that Medifast Inc will post -1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MED. Zacks Research downgraded shares of Medifast from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Weiss Ratings raised Medifast from a "sell (e+)" rating to a "sell (d)" rating in a research report on Monday. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Medifast presently has an average rating of "Reduce" and a consensus target price of $12.00.

Institutional Investors Weigh In On Medifast

Institutional investors and hedge funds have recently bought and sold shares of the business. Amundi lifted its holdings in shares of Medifast by 43.5% during the 1st quarter. Amundi now owns 30,439 shares of the specialty retailer's stock worth $398,000 after acquiring an additional 9,224 shares during the period. AQR Capital Management LLC increased its stake in Medifast by 14.5% in the first quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer's stock valued at $2,693,000 after acquiring an additional 25,366 shares during the period. Strs Ohio acquired a new position in Medifast in the first quarter worth about $78,000. JPMorgan Chase & Co. raised its position in Medifast by 2.5% in the second quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer's stock worth $749,000 after purchasing an additional 1,316 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in Medifast during the second quarter worth about $200,000. Institutional investors own 95.51% of the company's stock.

Medifast Company Profile

Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source